R Street Institute31mOpinion
Trump: Look at the Slow-Moving FDA
The Food and Drug Administration’s approval of low-risk tobacco pouches is welcome, but why did it delay for more than four ...
Lay's potato chips recall upgraded to FDA's most serious level. Is Ohio affected?
Lays recalled their classic chips in December 2024. Now, there's a new status to the ongoing recall. According to ...
FDA approves Ozempic to help reduce risk of worsening chronic kidney disease
The FDA’s approval of Ozempic to battle chronic kidney disease “allows us to more broadly address conditions within cardiovascular-kidney-metabolic syndrome, which affects millions of ...
Salad Recall Update as FDA Sets Highest Risk Level
The U.S. Food and Drug Administration ( FDA) has set its highest risk level—a Class I recall—over potential salmonella contamination in salad products.
Health.com2h
Lay’s Potato Chips Recall: FDA Sets Highest Risk Level for Over 6,000 Bags
The FDA just set the highest risk level—class 1—for the recall of Lay's Classic Potato Chips amid concern that they contain ...
The FDA’s new, same-old food labels demand better obesity solutions
All things considered, it’s at least as likely to make health outcomes worse as it is to make most people healthier.
CNET2h
Red Dye No. 3 Can be Found in These 9 Foods in Your Pantry
After the Red No. 3 ban, there are now eight color additives approved by the FDA. They are FD&C Blue No. 1, FD&C Blue No. 2, ...
Sunscreen Recalled Nationwide as FDA Sets Risk Level
A voluntary recall was initiated by The W.S. Badger Company due to missing labels on a sunscreen product distributed ...
The American Journal of Managed Care3h
FDA-Approved IV Iron Formulations
Panelists discuss how modern FDA-approved intravenous iron formulations, including ferric carboxymaltose, ferumoxytol, and ...
MLive3h
Lay’s potato chip recall now elevated to FDA’s highest-risk level
The FDA has upgraded a recall of Lay’s Potato Chips to the highest level possible, meaning consuming the chips will cause ...
FierceBiotech5h
Takeda axes failed epilepsy asset after FDA weighs in on data package
Takeda has axed plans to seek approval for its failed epilepsy drug candidate soticlestat. The Japanese drugmaker pulled the plug on the program after the FDA pointed out the shortcomings of its ...
Healio6h
Decentralized clinical trials: FDA guidance and the ‘new modus operandi’
The COVID-19 pandemic forced investigators conducting clinical trials to use decentralized elements, such as telehealth, to ...